Trademagazin > News and articles > Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics
Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics
Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.
Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.
In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.
ESM
Related news
Nestlé launches pair of initiatives to decarbonize cocoa supply chain
The global food company said its new projects aim to…
Read more >Cerbona acquires BOCI, which marks a new chapter in the story of the iconic brand
Nestlé has announced the sales of its BOCI, MELBA and…
Read more >
More related news >
Related news
Seven trends shaping in-store marketing and retail design in 2024
Smart brands know that in-store marketing and store design can…
Read more >2024 is a year of challenges for the tobacco industry and retail
Annual tobacco retail sales are expected to have increased in…
Read more >The latest issue of Trade magazine is out now!
The digital version is available with more content once again,…
Read more >